Compare CSTL & UHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTL | UHT |
|---|---|---|
| Founded | 2007 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.8M | 561.5M |
| IPO Year | 2019 | 1995 |
| Metric | CSTL | UHT |
|---|---|---|
| Price | $34.49 | $39.05 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | ★ $45.50 | $43.00 |
| AVG Volume (30 Days) | ★ 275.5K | 81.1K |
| Earning Date | 05-06-2026 | 04-27-2026 |
| Dividend Yield | N/A | ★ 7.33% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | ★ $344,229,000.00 | $99,190,000.00 |
| Revenue This Year | $2.42 | $2.12 |
| Revenue Next Year | $12.69 | $2.94 |
| P/E Ratio | ★ N/A | $50.27 |
| Revenue Growth | ★ 3.66 | 0.18 |
| 52 Week Low | $17.72 | $35.26 |
| 52 Week High | $44.28 | $46.30 |
| Indicator | CSTL | UHT |
|---|---|---|
| Relative Strength Index (RSI) | 58.21 | 32.64 |
| Support Level | $22.88 | $38.11 |
| Resistance Level | $42.03 | $42.79 |
| Average True Range (ATR) | 1.44 | 0.85 |
| MACD | 0.01 | -0.13 |
| Stochastic Oscillator | 57.86 | 7.17 |
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.